Published in Cancer Gene Ther on June 18, 2010
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine (2011) 0.98
CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. PLoS One (2013) 0.93
SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res (2014) 0.87
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Rev Vaccines (2014) 0.85
A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo. Biomed Res Int (2013) 0.81
4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression. PLoS One (2016) 0.78
Novel technologies to engineer graft for tolerance induction. Curr Opin Organ Transplant (2016) 0.78
Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell (1996) 9.03
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity (1998) 4.23
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 3.72
Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A (1993) 2.76
Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol (1993) 2.40
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med (2000) 2.18
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Characterization and crystallization of core streptavidin. J Biol Chem (1987) 2.09
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Gene therapy: promises and problems. Annu Rev Genomics Hum Genet (2001) 1.82
Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70
Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol Rev (2008) 1.49
Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol (2007) 1.48
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol (2007) 1.48
T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med (1994) 1.43
NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood (2005) 1.43
The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol (2001) 1.31
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood (2003) 1.27
Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther (1991) 1.27
Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res (2009) 1.26
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity (2002) 1.19
4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol (1999) 1.05
Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol (2001) 1.04
LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM. J Leukoc Biol (2005) 1.04
Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. J Immunother (2005) 1.01
Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. J Immunol (2008) 0.97
Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery (2007) 0.93
LIGHT Is critical for IL-12 production by dendritic cells, optimal CD4+ Th1 cell response, and resistance to Leishmania major. J Immunol (2007) 0.93
Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res (2007) 0.90
Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon. Exp Mol Pathol (2006) 0.88
Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev (2008) 0.87
Gene therapy. The best of times, the worst of times. Science (2000) 0.86
Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo. Hum Gene Ther (2006) 0.82
The effect of LIGHT in inducing maturation of monocyte-derived dendritic cells from MDS patients. Cancer Immunol Immunother (2004) 0.81
Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Mol Cancer Ther (2003) 0.81
A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res (2003) 0.81
Impaired expression of CD28 on T cells in hairy cell leukemia. Clin Immunol (1999) 0.80
An examination of tumor antigen loss in spontaneous metastases. Invasion Metastasis (1981) 0.78
A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo. Cancer Immunol Immunother (2004) 0.78
Tumor immunity to murine plasma cell tumors. VII. Expression of H-2 and tumor antigens on Ig synthesis variants of MPC-11. Int J Cancer (1982) 0.77
Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver. Transplant Proc (1997) 0.83
Alternative splicing of class Ib major histocompatibility complex transcripts in vivo leads to the expression of soluble Qa-2 molecules in murine blood. Proc Natl Acad Sci U S A (1994) 0.83
Genetic control of the humoral immune response to xenografts. II. Monoclonal antibodies that cause rejection of heart xenografts are encoded by germline immunoglobulin genes. Transplantation (1995) 0.79
The humoral response to xenografts is controlled by a restricted repertoire of immunoglobulin VH genes. Transplantation (1998) 0.79
Engineering of bone marrow cells with fas-ligand protein-enhances donor-specific tolerance to solid organs. Transplant Proc (2011) 0.77
Induction of allograft nonresponsiveness after intrathymic inoculation with donor class I allopeptides. I. Correlation of graft survival with antidonor IgG antibody subclasses. Transplantation (1997) 0.76
Immunomodulation with SA-FasL protein as an effective means of preventing islet allograft rejection in chemically diabetic NOD mice. Transplant Proc (2013) 0.76
Mouse xenoantigens contribute to rat T-cell Vbeta repertoire generation in mixed xenogeneic bone marrow chimeras. Immunology (2000) 0.75
Posttransplantation systemic immunomodulation with SA-FasL-engineered donor splenocytes has robust efficacy in preventing cardiac allograft rejection in mice. Transplant Proc (2013) 0.75
Autoimmune responses regulate alloimmunity for prolonged cardiac allograft survival. Transplant Proc (2001) 0.75
Expression of FasL as a stable cell-surface molecule is important to its apoptotic function. Transplant Proc (2001) 0.75
The rejection of hamster xenografts by rats is mediated by a restricted repertoire of Ig heavy chain variable genes. Transplant Proc (1996) 0.75
The role of indirect recognition and TH2 response in cardiac xenograft rejection. Transplant Proc (2001) 0.75
Genetic evidence that the antibody response to xenografts is directed at a restricted number of target antigens. Transplant Proc (1997) 0.75
Rat peripheral T-cell receptor V beta repertoire in F344-to-B10 (rat-to-mouse) mixed xenogeneic chimeras. Transplant Proc (1999) 0.75
[Genetic control of humoral immune response to xenografts. A monoclonal antibody that causes the hyperacute rejection of cardiac xenografts uses the genes in a native form]. Chirurgie (1996) 0.75
Modulation of alloimmunity with class I MHC peptides: mechanisms of action. Transplant Proc (1999) 0.75
Germline VH gene usage in xenoreactive monoclonal antibody. Transplant Proc (1996) 0.75
Intragraft cytokine gene expression in human liver allografts. Liver Transpl Surg (1995) 0.75